



Ebert M, kidney transplant recipient

65+ accepted abstracts involving CareDx solutions across the transplant journey.

Туре	Title	Author/Presenter	Session Date and Time
KIDNEY			
OUTCOMES			
Oral	Ibox Prognostication in Kidney Transplant Recipients Who Undergo Belatacept Conversion for Chronic Active Antibody Mediated Rejection	D. Kumar	June 5, 4:30 PM-4:40 PM Room 3 Upper Level
Oral	Extended Validation of the iBox in Real Life Setting, Different Transplant Systems and Clinical Trials: The iBox EXTENDED Trial	S. Naser	June 6, 5:20 PM-5:30 PM Ballroom 6F Upper Level
Poster	Donor-Derived Cell-Free DNA (dd-cfDNA) Results and Clinical Outcomes in Antibody Mediated Rejection (ABMR)	T. Dhaliwal	June 3, 5:30 PM-7:00 PM Board no. A190
Poster	Characteristics and Outcomes of Kidney Transplant Recipients with Rejection and Marked Elevations in Donor-Derived Cell-Free DNA (dd-cfDNA)	G. Shekhtman	June 5, 9:15 AM–9:55 AM Board no. C138
Poster	Integrating Data from Early Kinetic dd-cfDNA After Transplantation and Ibox to Predict Long-Term Renal Graft Outcomes	E. Cuadrado-Payán	June 5, 9:15 AM–9:55 AM Board no. C150
Poster	Using Donor-Derived Cell-Free DNA (dd-cfDNA) to Diagnose Subclinical Rejection - An Analysis of 256 Patients at a Single Institution's 3-Year Study	R. Mendel	June 5, 9:15 AM–9:55 AM Board no. C127
IMMUNOSUI	PPRESSION MANAGEMENT		
Oral	The Role of the Molecular Microscope and Donor Derived Cell Free DNA to Guide Therapy for T-Cell Mediated Rejection in Kidney Transplants	D. Kumar	June 5, 3:50 PM-4:00 PM Room 2 Upper Level
Poster	Minimization in Belatacept-Treated Kidney Transplant Recipients Guided by Combined Allosure and Trugraf Monitoring	T. Vanhove	June 4, 9:15 AM-9:55 AM Board no. B204
Poster	Serial Donor Derived Cell Free DNA Monitoring During Belatacept Conversion in Kidney Transplant Recipients	A. Athreya	June 5, 9:15 AM–9:55 AM Board no. C145
REJECTION /	INJURY		
Oral	Optimizing Urinary Cell Mrna Profiling of Kidney Allograft Recipients: Development of a Home Processing Protocol for Noninvasive Diagnosis of T Cell Mediated Rejection and BK Virus Nephropathy	T. Salinas	June 4, 3:50 PM-4:00 PM Ballroom 6C Upper Level
Oral	Development and Validation of an Integrative Dd-Cfdna System to Predict Allograft Rejection: An International Population Based Study	O. Aubert	June 4, 4:10 PM-4:20 PM Ballroom 6C Upper Level

Туре	Title	Author/Presenter	Session Date and Time
KIDNEY COI	N'D		
REJECTION / IN	UURY CON'D		
Oral	Evaluation of HistoMap Molecular Model for Renal Allograft Rejection Diagnosis in Biopsies with Suspicious Histologic Findings for Antibody-Mediated Rejection	I. Moinuddin	June 4, 4:50 PM–5:00 PM Room 2 Upper Level
Poster	Antibody-Mediated Rejection (ABMR): Role of Donor-Derived Cell-Free Dna, Mmdx, and Traditional Histology in the Diagnosis and Management of Abmr Phenotypes	A. Rizvi	June 3, 5:30 PM-7:00 PM Board no. A191
Poster	Association Between Donor-Derived Cell-Free DNA (dd-cfDNA), HLA, and Non-HLA Antibodies in Kidney Transplant Recipients with Antibody-Mediated Rejection	E. Kitchel	June 3, 5:30 PM-7:00 PM Board no. A189
Poster	Donor-Derived Cell-Free DNA Utility in Differentiating Acute versus Chronic Active Antibody-Mediated Rejection	A. Rizvi	June 3, 5:30 PM-7:00 PM Board no. A200
Poster	Donor-derived Cell-Free DNA (dd-cfDNA) in Patients with Antibody Mediated Rejection (ABMR) and Non-HLA Donor-Specific Antibodies (DSA)	A. Wadhwa	June 3, 5:30 PM-7:00 PM Board no. A186
Poster	Mixed Rejection: Utility of Donor-Derived Cell-Free DNA, Mmdx, and Traditional Histology in the Diagnosis and Management of Combined Antibody-Mediated and T-Cell Mediated Rejection	A. Rizvi	June 3, 5:30 PM-7:00 PM Board no. A192
Poster	dd-cfDNA and Allograft Injury Single Center Experience	P. Jain	June 5, 9:15 AM-9:55 AM Board no. C144
Poster	Non-Invasive Multimodality Testing with AlloSure and AlloMap Predicts Microvascular Inflammation (MVI) and Rejection After Kidney Transplant	S. Panzer	June 5, 9:15 AM-9:55 AM Board no. CLB023
Poster	Donor-Derived Cell-Free DNA (dd-cfDNA) Accurately Correlates with and Predicts Microvascular Inflammation (MVI) in Kidney Transplant Recipients	S. Panzer	June 5, 9:15 AM-9:55 AM Board no. C133
Poster	Donor-Derived Cell-Free DNA (dd-cfDNA) in 100 Kidney Transplant Recipients with Indication Biopsy - Results of a Prospective Single-Center Trial	L. Benning	June 5, 9:15 AM-9:55 AM Board no. C148
Poster	Donor-Derived Cell-Free DNA Accurately Identifies Allograft Injury in Kidney Transplant Recipients	M. Ajaimy	June 5, 9:15 AM-9:55 AM Board no. C155
Poster	Fetal and Donor-Derived Cell-Free Dna May Assist in Differentiating Pregnancy Related Changes from Allograft Rejection in Kidney Transplant Recipients	N. M. Ali	June 5, 9:15 AM-9:55 AM Board no. C170
Poster	Validation of HistoMap Molecular Model for Renal Allograft Rejection Diagnosis in a Multi-Center Cohort Study	N. Garg	June 6, 9:45 AM-10:25 AM Board no. D171
SURVEILLANC	E		
Poster	Analysis of Donor-Derived Cell-Free DNA (dd-cfDNA) in En Bloc and Single Kidney Transplants from Small Pediatric Donors	T. Ruder	June 3, 5:30 PM-7:00 PM Board no. A069
Poster	Range of Donor Derived Cell Free DNA in Liver Transplant Recipients - An Exploratory Analysis	K. Modi	June 3, 5:30 PM-7:00 PM Board no. A068
Poster	Association of Donor-Derived Cell Free DNA and Histology in Kidney Transplant Recipients with BKPyV Viremia	P. Johnson	June 5, 9:15 AM-9:55 AM Board no. C129
Poster	Clinical Management of Pregnant Transplant Recipients: Utilization of Fetal Fraction and dd-cfDNA	N. Khoury	June 5, 9:15 AM-9:55 AM Board no. C149
Poster	Clinical Utility of Donor-Derived Cell-Free Dna During the Period of Recovery of Renal Function After Kidney Transplantation	Y. Dreige	June 5, 9:15 AM-9:55 AM Board no. C142
Poster	Donor-Derived Cell-Free DNA and Blood Gene Expression Profiles in Clinically Stable Simultaneous Pancreas-Kidney Transplant Recipients	J. Graham	June 5, 9:15 AM-9:55 AM Board no. C283

Туре	Title	Author/Presenter	Session Date and Time		
KIDNEY CON	D'V				
SURVEILLANCE	E CON'D				
Poster	Donor-Derived Cell-Free Dna Surveillance in Kidney Transplant Recipients Receiving Belatacept-Based Maintenance Immunosuppression	P. Loarte	June 5, 9:15 AM-9:55 AM Board no. C164		
Poster	Donor-Derived Cell-Free Dna is Not Confounded by Cytomegalovirus Viremia in Kidney Transplant Recipients	N. M. Ali	June 5, 9:15 AM-9:55 AM Board no. C166		
Poster	Donor-Drived Cell-Free Dna Levels Are Predictive of Rejection in a Prospective Trial of Hiv-Positive Kidney Transplant Recipients	M. L. Holzner	June 5, 9:15 AM-9:55 AM Board no. C136		
Poster	Early Experience Using Donor-Derived Cell-Free Dna for the Surveillance of Alloimmune Injury in Kidney Transplantation	J. Silvano	June 5, 9:15 AM-9:55 AM Board no. C153		
Poster	Effect of Donor and Recipient Characteristics on Donor Derived Cell Free Dna Levels Upto One Year Post Kidney Transplant	A. Mirza	June 5, 9:15 AM-9:55 AM Board no. C156		
Poster	Evaluation of dd-cfDNA Measures in Kidney Transplant Recipients More Than Two Years Post-Transplantation	M. R. Weir	June 5, 9:15 AM-9:55 AM Board no. C137		
Poster	Donor-Derived Cell-Free DNA Kinetics in HCV-Positive Donor Organ Kidney Transplant Recipients	N. M. Ali	June 5, 9:15 AM-9:55 AM Board no. CLB022		
Poster	High Levels of Donor Derived Cell-Free Dna in the Early Post-Transplant Phase Indicates Injury Independent of Renal Function Status	A. D. Mattiazzi	June 5, 9:15 AM-9:55 AM Board no. C167		
Poster	Donor Derived Cell Free DNA Testing in a Kidney Transplant Recipient with FSGS Recurrence	A. Faravardeh	June 6, 9:45 AM-10:25 AM Board no. D261		
PEDIATRICS					
Oral	Utility of a Blood Gene Expression Profiling Score (AlloMap) to Predict Rejection Events in Pediatric Kidney Transplant Recipients	R. Dandamudi	June 6, 4:00 PM-4:10 PM Room 1A/B Upper Level		
Oral	Donor-Derived Cell-Free DNA Testing in Children: Indications and Utility	J. Chandar	June 6, 4:10 PM-4:20 PM Room 1A/B Upper Level		
Oral	Multicenter Experience Using Donor Derived Cell Free DNA in Pediatric Patients Less Than 20 Kg	J. Steinke	June 6, 4:50 PM-5:00 PM Room 1A/B Upper Level		
Poster	Absolute Copies is Better Than Percentage of Donor-Derived Cell-Free Dna as a Marker of Rejection and Graft Injury in Pediatric Kidney Transplantation	R. Dandamudi	June 6, 9:45 AM-10:25 AM Board no. D184		
Poster	Combination of Blood Gene Expression (AlloMap) and Donor Derived Cell Free DNA (Allosure) to Diagnose Allograft Rejection in Kidney Transplant Recipients	R. Dandamudi	June 6, 9:45 AM-10:25 AM Board no. D180		
Poster	Normalizing the Percent Donor Derived Cell Free Dna (% Dd-cfdna) to Recipient Body Surface Area (BSA) or to Donor to Recipient BSA Ratio: Effects on the Diagnostic Performance in Detecting Acute Transplant Rejection	R. Dandamudi	June 6, 9:45 AM–10:25 AM Board no. D182		
Poster	Urine Gene-Expression Profiling Score (UroMap) for Rejection Surveillance in Pediatric Kidney Transplantation	R. Dandamudi	June 6, 9:45 AM-10:25 AM Board no. D188		
Poster	Utility of Donor-Derived Cell-Free DNA and Tacrolimus Variability in Monitoring Early Post-Kidney Transplant Outcomes	R. George	June 6, 9:45 AM-10:25 AM Board no. D190		
DIGITAL	DIGITAL				
Poster	Feasibility and Impact of the Implementation of Remote Patient Monitoring Combined with Enhanced Education and Monitoring of Transplant Recipients	S. Khan	June 6, 9:45 AM-10:25 AM Board No. D232		

Title	Author/Presenter	Session Date and Time		
Impact of Continuously Elevated Donor-Derived Cell Free Dna Levels on Clinical Outcomes in Heart Transplant Patients	J. Mancuso	June 4, 4:50 PM-5:00 PM Ballroom 6D Upper Level		
Indeterminate Donor Derived Cell Free DNA Levels Are Not Associated with Subsequent Adverse Events in Heart Transplant Recipients	A. Varshney	June 4, 9:15 AM-9:55 AM Board no. B276		
Impact of Persistently Elevated Donor-Derived Cell Free DNA Levels on Clinical Outcomes After Heart Transplant	H. Farhoud	June 4, 9:15 AM-9:55 AM Board no. B279		
JURY				
Stratification of Biopsy Confirmed Rejection Severity Using Donor Derived Cell Free DNA and Gene Expression Profiling	C. Link	June 3, 4:35 PM-4:45 PM Ballroom 6D Upper Level		
Risk Stratification of Cardiac Allograft Injury Using Cell-Free DNA Testing - Real World Effectiveness	A. Saeyeldin	June 4, 9:15 AM-9:55 AM Board no. B263		
Where There is Smoke, There is Not Always Fire: Cell Free DNA Elevations without Rejection	S. S. Patlolla	June 4, 9:15 AM-9:55 AM Board no. B258		
Donor Derived Cell Free DNA (dd-cf DNA) and Cardiac Allograft Vasculopathy (CAV)	R. Alharethi	June 4, 9:15 AM-9:55 AM Board no. B266		
E				
A Modern Heart Transplant Rejection Surveillance Protocol Utilizing Cell-Free Dna Testing - A Single Center Experience	A. Saeyeldin	June 3, 4:25 PM-4:35 PM Ballroom 6D Upper Level		
Heartcare Across the Age Spectrum	M. Kamath	June 3, 4:35 PM-4:45 PM Ballroom 6F Upper Level		
Effect of COVID-19 Infection on HeartCare: Updated Data from the SHORE Multicenter Registry	Y. Brailovsky	June 3, 4:45 PM-4:55 PM Ballroom 6F Upper Level		
Covid-19 Vaccine Stimulation of Dsa and Dd-cfdna in Heart Transplant Patients	J. Thomas	June 3, 5:30 PM-7:00 PM Board no. A114		
Can't We All Just Get Along? Comparison of Cell Free DNA Technologies	A. Alam	June 4, 9:15 AM-9:55 AM Board no. B261		
Association Between Gene Expression Profiling Scores and Malignancy in Adult Heart Transplant Recipients	S. Bektur	June 4, 9:15 AM-9:55 AM Board no. B271		
It is Not Just Temperature Rising!!! The Impact of Active Viruses on Donor Derived Cell Free DNA Testing	H. I. Shakoor	June 4, 9:15 AM-9:55 AM Board no. B274		
Time to Eliminate Surveillance Endomyocardial Biopsies: Use of Donor Derived Cell-Free DNA for Heart Transplant Rejection Surveillance	D. J. Miklin	June 4, 9:15 AM-9:55 AM Board no. BLB017		
IJURY				
Plasma Inflammatory Markers Associated with Lung Allograft Injury	S. Weigt	June 3, 4:55 PM-5:05 PM Ballroom 6D Upper Level		
SURVEILLANCE				
Donor Derived Cell-Free DNA Levels within the First 30 Days Post Transplant in Patients Receiving Intraoperative Cardiopulmonary Support	M. Botros	June 5, 9:15 AM-9:55 AM Board no. C273		
	Impact of Continuously Elevated Donor-Derived Cell Free Dna Levels on Clinical Outcomes in Heart Transplant Patients Indeterminate Donor Derived Cell Free DNA Levels Are Not Associated with Subsequent Adverse Events in Heart Transplant Recipients Impact of Persistently Elevated Donor-Derived Cell Free DNA Levels on Clinical Outcomes After Heart Transplant IURY Stratification of Biopsy Confirmed Rejection Severity Using Donor Derived Cell Free DNA and Gene Expression Profiling Risk Stratification of Cardiac Allograft Injury Using Cell-Free DNA Testing - Real World Effectiveness Where There is Smoke, There is Not Always Fire: Cell Free DNA Elevations without Rejection Donor Derived Cell Free DNA (dd-cf DNA) and Cardiac Allograft Vasculopathy (CAV) A Modern Heart Transplant Rejection Surveillance Protocol Utilizing Cell-Free Dna Testing - A Single Center Experience Heartcare Across the Age Spectrum Effect of COVID-19 Infection on HeartCare: Updated Data from the SHORE Multicenter Registry Covid-19 Vaccine Stimulation of Dsa and Dd-cfdna in Heart Transplant Patients Can't We All Just Get Along? Comparison of Cell Free DNA Technologies Association Between Gene Expression Profiling Scores and Malignancy in Adult Heart Transplant Recipients It is Not Just Temperature Rising!!! The Impact of Active Viruses on Donor Derived Cell Free DNA Testing Time to Eliminate Surveillance Endomyocardial Biopsies: Use of Donor Derived Cell-Free DNA for Heart Transplant Rejection Surveillance	Impact of Continuously Elevated Donor-Derived Cell Free Dna Levels on Clinical Outcomes in Heart Transplant Patients Indeterminate Donor Derived Cell Free DNA Levels Are Not Associated with Subsequent Adverse Events in Heart Transplant Recipients Impact of Persistently Elevated Donor-Derived Cell Free DNA Levels on Clinical Outcomes After Heart Transplant IJURY Stratification of Biopsy Confirmed Rejection Severity Using Donor Derived Cell Free DNA and Gene Expression Profiling Risk Stratification of Cardiac Allograft Injury Using Cell-Free DNA Testing - Real World Effectiveness A. Saeyeldin World Effectiveness Where There is Smoke, There is Not Always Fire: Cell Free DNA Elevations without Rejection Donor Derived Cell Free DNA (dd-cf DNA) and Cardiac Allograft Vasculopathy (CAV) R. Alharethi Effect of COVID-19 Infection on HeartCare: Updated Data from the SHORE Heartcare Across the Age Spectrum M. Kamath Effect of COVID-19 Infection on HeartCare: Updated Data from the SHORE Wulticenter Registry Covid-19 Vaccine Stimulation of Dsa and Dd-cfdna in Heart Transplant Patients J. Thomas Can't We All Just Get Along? Comparison of Cell Free DNA Technologies A. Alam Association Between Gene Expression Profiling Scores and Malignancy in Adult Heart Transplant Recipients It is Not Just Temperature Rising!! The Impact of Active Viruses on Donor Derived Cell Free DNA Testing Time to Eliminate Surveillance Endomyocardial Biopsies: Use of Donor Derived Cell-Free DNA for Heart Transplant Rejection Surveillance Donor Derived Cell-Free DNA Levels within the First 30 Days Post Transplant in M. Botros		

To learn more about CareDx in San Diego 2023, please visit https://start.caredx.com/sd-2023

